The effectiveness of pharmacological therapies is dependent in part on patient persistency with the prescribed therapeutic regimen. In the case of non-specific non-steroidal anti-inflammatory drugs (NSAIDs), effectiveness is often compromised by undesirable side-effects, poor compliance or discontinuation of therapy. While patterns of utilization of non-specific NSAIDs have been investigated, few data are available on the patterns of persistency for cyclooxygenase (COX)-2-specific inhibitors. This study used a provincial health-care system database in Quebec, Canada, to determine the duration of treatment in new users of COX-2-specific inhibitors and non-specific NSAIDs over the first 3 months of treatment, and to characterize the factors associated with treatment persistency. Results demonstrate that the median duration of treatment was longer among patients initially prescribed COX-2-specific inhibitors (30 days and 23 days for celecoxib and rofecoxib respectively) than in those prescribed non-selective NSAIDs (10 days). Although the percentage of patients remaining on COX-2-specific drugs declined over the course of treatment, few patients on either celecoxib or rofecoxib switched drugs, either to the other COX-2-specific inhibitor or to non-specific NSAIDs. Factors associated with persistent drug use were: COX-2-specific inhibitors, age, and the use of gastroprotective agents either at treatment initiation or during follow-up. Dosage, chronic disease score and prescriber's speciality were only marginally associated with persistency. Prior use of gastroprotective agents was associated with lower persistency. Although the limitations of this study, which included lack of information on the indication for the prescription and the reason for switch or discontinuation, preclude definite conclusions regarding patterns of use of these drugs, the data suggest that the use of COX-2-specific inhibitors may result in increased persistency with treatment.
Randomized clinical trials are essential for demonstrating the efficacy of a drug under carefully controlled conditions. However, in clinical practice, a drug's effectiveness is dependent not only on its efficacy but also on a variety of factors, such as appropriate use of the drug by the patient, which includes compliance or persistency with the prescribed drug regimen. Any changes in utilization, such as discontinuation or poor compliance, reduce the drug's effectiveness and affect clinical outcomes. Conversely, patient persistency is more likely to occur for a drug that demonstrates efficacy as well as tolerability.
In the case of non-specific non-steroidal antiinflammatory drugs (NSAIDs), it has been suggested previously that compliance may be a useful indication of efficacy [1, 2] . However, changes in non-specific NSAID utilization, such as drug switching or discontinuation, are common among patients and result from undesired Correspondence to: Y. Moride, Faculty of Pharmacy, Universite´de Montre´al, C.P. 6128, succ. Centre-ville, Montre´al, Quebe´c H3T 3J7, Canada. E-mail: yola.moride@umontreal.ca side-effects or less than optimal efficacy [3, 4] . A limited number of studies have investigated the patterns of non-specific NSAID utilization [3] [4] [5] .
The cyclooxygenase (COX)-2-specific inhibitors were developed to provide similar efficacy to non-specific NSAIDs by inhibiting the proinflammatory COX-2 enzyme while sparing the gastroprotective COX-1. The COX-1-sparing effect results in improved gastrointestinal safety, and since there is no platelet inhibition there is also a lower risk of bleeding. Clinical trials and outcome studies have supported this efficacy and safety profile [6] [7] [8] [9] ; N. M. Agrawal, G. Eisen, J. Fort et al., submitted for publication], and these drugs are widely used for the treatment of painful and inflammatory conditions, including osteoarthritis, rheumatoid arthritis, tendonitis/bursitis and primary dysmenorrhoea.
Despite the widespread use of COX-2-specific inhibitors, there are very few data on patterns of use of these drugs in a real-life setting. The purpose of the present study was to investigate the persistency and patterns of use of COX-2-specific inhibitors compared with nonspecific NSAIDs in a Canadian provincial health care system.
Design and methods

Population
A retrospective cohort study was conducted using data obtained from the databases of the Quebec drug and medical services plans. While the medical services plan is universal for all Quebec residents, the drug plan includes the vast majority of the elderly population in Quebec, as well as all welfare recipients and individuals who do not have access to private drug reimbursement programmes (e.g. self-employed people).
The Pharmaceutical Services Database was used to assemble the cohort and assess patterns of prior and current drug usage, and the Medical Services Database was used to identify factors related to gastrointestinal history.
A sample of 100 000 drug plan members who were dispensed at least one COX-2-specific inhibitor (celecoxib, rofecoxib) in the year 2000 was randomly selected. This sample size corresponded to 41.7% of all COX-2-specific inhibitors used by public drug plan members during that year. A sample of 60 000 non-specific NSAID users was also randomly selected during the same time period, and patients who used only low-dose aspirin ( 325 mg/day) were subsequently excluded.
The status of the patients with respect to being a user of either COX-2-specific inhibitors or non-specific NSAIDs was determined at the end of the study year, consistent with a cumulative incidence sampling strategy. Patients who had received both a COX-2-specific inhibitor and a non-specific NSAID during that year were considered to be COX-2-specific inhibitor users. The index prescription date was the first dispensing of a COX-2-specific inhibitor or a non-specific NSAID during the year 2000, and was limited to the period between 1 January and 31 August to allow computation of treatment duration over a period of 3 months. For inclusion in the study, drug plan members were required to be at least 18 yr of age and have continuous coverage for the 2 yr prior to the index prescription date. The requirement for prior coverage ensured that a medical history would be available for the patient.
Additionally, only incident COX-2-specific inhibitor or non-specific NSAID use was evaluated, defined as patients who had not received any NSAID (with the exception of low-dose aspirin) in the 365 days prior to the index date.
Dependent variables
Although the main outcome of interest was persistency, discontinuation was modelled as the dependent variable for methodological reasons. A treatment was considered discontinued if there was no subsequent dispensing, or if the next dispensing occurred after 1 month following the predicted end of the active prescription (predicted as a function of the date of initial dispensing and the prescribed duration). Persistency was the inverse of discontinuation and was measured as a binary variable at 1 month and 3 months of treatment.
Because of the use of a cumulative incidence sampling strategy, non-specific NSAID users could not switch to a COX-2-specific inhibitor, otherwise they would have been included in the group of COX-2-specific inhibitor users. Therefore, comparisons for persistency between COX-2-specific inhibitors and non-specific NSAIDs involved only the class of product initially prescribed.
The database includes, for each drug dispensed, the following information: patient identifier (anonymous), drug name, date of dispensing, quantity, dose per unit of administration, prescribed treatment duration, prescriber identifier (anonymous) and speciality. Treatment duration was calculated from the dates of dispensing and the prescribed duration. A treatment was considered discontinued if no other dispensing followed, or if the next dispensing occurred after 1 month following the predicted end of the active prescription. Predicted end was calculated as (predicted starting date þ prescribed duration) À 1.
For each of the COX-2-specific inhibitors, treatment duration was assessed as the number of days of active prescription for the product initially dispensed (no switch allowed). For non-specific NSAIDs, total treatment duration was the number of days of active prescription with any drug of that class. Therefore, users were allowed to switch from one product to another as long as they remained in the non-specific NSAID group. When the product remained the same throughout treatment, total duration corresponded to the period between the first dispensing date and the predicted end of the last prescription in order to account for poor compliance or prescription use. In the case of overlapping prescriptions of the same product, it was assumed that the patient finished the previous dispensing before starting the next. Total duration was therefore the sum of individual durations. For non-specific NSAIDs, when products were switched, total duration was the sum of individual treatment duration minus the overlapping time periods. It was assumed that the patient did not complete the first dispensing when the treatment was switched and that the new product was started on the date of dispensing.
Independent variables
The associations between persistency and the following characteristics were examined: drug class (COX-2-specific inhibitors vs non-specific NSAIDs, celecoxib vs rofecoxib), age group, gender, income level, dosage category (i.e. analgesic, anti-inflammatory, or higher than recommended for antiinflammatory effect), history of gastropathy (assessed through the prior dispensing of gastroprotective agents), overall health iii18 Y. Moride et al.
status (assessed by the chronic disease score) [10] , and medications that are contraindications for traditional nonspecific NSAID use (i.e. corticosteroids, anticoagulants). Use of gastroprotective agents was also assessed during the followup, using two distinct time windows. The first time frame was use at initiation of NSAID treatment (i.e. dispensing on index date or up to 2 days later), and the second time frame was first dispensing during NSAID treatment. The daily dosage of the COX-2-specific inhibitors and the non-specific NSAIDs at the index date was derived from the dose per unit, quantity dispensed and prescribed duration. Daily dosages were subsequently categorized into low, standard and high dosages. Standard dosages were the recommended anti-inflammatory dosages. The threshold for low dosages corresponded to the maximum approved over-thecounter dose or dosages less than the recommended antiinflammatory dose. High dosages were those above the maximum recommended anti-inflammatory dose.
Statistical analyses
Descriptive analyses were conducted on the duration of use expressed as a categorical variable (persistency at 1 month and 3 months). Subsequently, survival curves were obtained for each drug class in order to characterize treatment discontinuation over the first 3 months of treatment. In these analyses, treatment discontinuation was modelled as failure. The Cox proportional hazards model was used to identify factors associated with treatment discontinuation, controlling simultaneously for all covariables. Since the indication for drug prescription was not available in the database, it was not possible to differentiate between discontinuation due to an indication requiring short-term use and discontinuation due to intolerance, inefficacy or poor compliance. The exclusion of users of low-dose aspirin only led to the exclusion of use for prevention of cardiovascular disease. We also considered dosages that potentially reflect indication (i.e. analgesic vs antiinflammatory effect). Despite these adjustments, the potential for confounding by indication remains. Consequently, multivariate analyses were restricted to the population of users who persisted at least beyond the first month of treatment. The intention was to eliminate acute indications or infrequentas-necessary use, and to try to provide a more homogeneous study population.
All independent variables described above were included in the model. The strength of the association between a given covariable and the probability of discontinuation was assessed by calculation of hazard ratios. Because the outcome of interest was persistency as opposed to discontinuation, the inverse of the hazard ratios produced by the Cox proportional hazards model was reported. Statistical uncertainty was assessed by calculating 95% confidence intervals.
Results
Of the random sample of patients identified from the database, 22 306 celecoxib users, 10 482 rofecoxib users and 4784 users of non-specific NSAIDs met the inclusion criteria of the study.
The mean age was similar among patients prescribed the two COX-2-specific inhibitors (66.7 and 64.2 yr for celecoxib and rofecoxib respectively) and was higher than that of patients prescribed non-specific NSAIDs. Differences in gender distribution were also observed among the populations, the COX-2 specific inhibitors having a higher proportion of females (67.7 and 66.0% for celecoxib and rofecoxib respectively) than the NSAIDs (54.0%).
Median duration of treatment over the first 3 months was greater for celecoxib than rofecoxib (30 and 23 days respectively) and non-specific NSAIDs (10 days).
The rates of persistency for celecoxib and rofecoxib at 1 month and the cumulative rates at 3 months are shown in Table 1 . At both the 1-month and 3-month time points, only a small proportion of patients switched medications, either to the other COX-2-specific inhibitor or to a non-specific NSAID. Persistency was maintained in 52.4% of celecoxib users and 45.6% of rofecoxib users over 1 month, but there was a noticeable decrease in persistency over the subsequent months; only 19.3% of patients who were using celecoxib and 13.3% of patients using rofecoxib remained on therapy after the third month. The corresponding figures for non-specific NSAIDs were 15.1 and 3.4% at 1 month and 3 months respectively.
The median time to a switch to the other COX-2-specific inhibitor was greater for celecoxib than rofecoxib. However, it was observed that the median time to a switch in medication was shorter in patients who switched to a non-specific NSAID (21 days for celecoxib, 24 days for rofecoxib) than in patients who switched from celecoxib to rofecoxib (42 days) and from rofecoxib to celecoxib (34 days). Figure 1 presents a survival function analysis of the 3-month persistency based on the patients' initial prescriptions. The two COX-2-specific inhibitors demonstrated similar patterns of persistency, while the nonspecific NSAIDs resulted in a higher and more rapid rate of discontinuation/switching. However, it should be noted that for both types of drugs there were large dropouts at similar time points, at approximately 10 days and again at about 30 days. The median duration of treatment stratified by age and by initial dosage is shown in Fig. 2 . Among all three groups, there was a trend towards greater persistency with increasing age, and towards less persistency with increasing dosage. Table 2 presents the results of a Cox proportional hazards analysis, adjusted for differences in patient and treatment characteristics. As shown in the table, patients prescribed either celecoxib or rofecoxib were more likely to show persistency than patients prescribed non-specific NSAIDs. Other factors associated with persistency included increased age, the use of gastroprotective agents at treatment initiation or during the follow-up, a higher chronic disease score, and being prescribed an agent by a specialist rather than a general practitioner. Factors associated with lower persistency included high initial dose and prior use of gastroprotective agents.
Contraindications for the use of non-specific NSAIDs, such as the concomitant use of anticoagulants and corticosteroids, had no significant effect on persistency. Similarly, income level and gender were not associated with persistency.
Discussion
The results presented here demonstrate a low persistency of use of COX-2-specific inhibitors and non-specific NSAIDs beyond 1 month among patients in a Canadian provincial health plan where the prescription of these agents is not restricted for reimbursement. However, the data also show that a greater proportion of patients remained on COX-2-specific inhibitor therapy than on non-specific NSAIDs, with greater persistency for celecoxib than for rofecoxib.
While the cyclical nature of the pain states for which these drugs are prescribed is likely to contribute to their intermittent use, discontinuation and/or switching of drugs among users of non-specific NSAIDs are generally associated with a lack of efficacy or gastrointestinal intolerability. In particular, gastrointestinal intolerance has been reported to be the primary reason for patients stopping or switching drugs [11] . In the present study, the reasons for the low rate of persistency are unclear because the causes of discontinuation and switching were not investigated. Despite this limitation, both the median duration of treatment and the survival curves suggest higher rates of persistency among new users of COX-2-specific inhibitors than among new users of non-specific NSAIDs. An additional limitation was that the indication resulting in the prescription of either the non-specific NSAIDs or the COX-2-specific inhibitors was not available. Thus, it is possible that, at least for a proportion of patients, the prescription was for an acute or non-chronic condition. The almost simultaneous dropout of patients taking COX-2-specific inhibitors and non-specific NSAIDs at 10 and 30 days on the survival analysis curves may support this possibility.
The Cox proportional hazards analysis further suggests that persistency may be related to more chronic conditions, as demonstrated by increased age and higher chronic disease score being associated with greater persistency. Although a previous study suggested that both chronic and non-chronic indications were equally associated with the probability of a switch between drugs among repeat users, that study was performed prior to the introduction of COX-2-specific inhibitors [3] . The positive association between persistency and a specialist prescriber rather than a general practitioner may lend further support to the possibility that severity of the indication plays a role in patient persistency.
In contrast, the prior use of gastroprotective agents resulted in lower persistency, suggesting that these patients may be more cautious in their use of antiinflammatory drugs. Gastroprotective agents are commonly coprescribed with non-specific NSAIDs, either prophylactically or symptomatically, and a recent study of drug-switching patterns among users of non-specific NSAIDs reported an increased probability of gastroprotective agent use among patients switching drugs [4] . It may therefore be of relevance to note that, in the present study, concomitant use of gastroprotective agents was associated with a greater likelihood of persistency. However, since neither the reason for prescribing gastroprotective agents nor the treatment regimen for which these drugs were prescribed (i.e. non-specific NSAIDs or COX-2-specific inhibitors) was determined, interpretation and clinical extrapolation of these outcomes should be approached with caution.
Importantly, the prescribing of COX-2-specific inhibitors was more likely to result in persistency. Whether this was due to better gastrointestinal safety and tolerability in the general population, as predicted from the clinical trial profile of these drugs, or the channelling of patients perceived as being at higher risk of gastrointestinal intolerability or adverse events, could not be ascertained. In this respect it should be noted that the mean age of patients prescribed COX-2-specific inhibitors was higher than that of patients prescribed the non-specific NSAIDs, suggesting channelling. However, the lack of control for all confounding factors, which could contribute to differences in persistency, is a further study limitation.
These results are only generalizable to the year 2000, because the interval of the study represents an unstable time period. This instability is a consequence of the introduction of new drugs into the market, in this case the COX-2-specific inhibitors, which often results in the perturbation of pre-existing prescribing patterns [12] and the over-representation of single or trial prescriptions. Similarly, the databases used in this study may not be representative of other populations or health plans, even within the Canadian health system (the prescription of the COX-2 inhibitors being unrestricted in Quebec).
In summary, there appear to be important differences in persistency rates between COX-2-specific inhibitors and non-specific NSAIDs, the former demonstrating the longer duration of use. Treatment persistency relates to a number of factors in addition to drug class, several of which may be associated with disease severity or chronicity. However, additional analyses are needed, not only to identify the indications for drug use and the reasons for discontinuation or switching, but also to provide a more extensive medical history of the patients, especially with regard to the presence of potential risk factors for gastrointestinal adverse events. Future studies should also evaluate the association between rates of persistency, especially the higher rates observed with COX-2-specific inhibitors, and patient outcomes. 
